Nexterone (amiodarone Hci) Injection, Solution
Product Images NDC 51662-1481

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Nexterone (amiodarone Hci) (NDC 51662-1481). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Hf Acquisition Co Llc, Dba Healthfirst, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Principal Display Panel (51662-1480-1 BAG LABEL)

Label for Nexterone (amiodarone HCl) Premixed Injection, 150 mg/100 mL (1.5 mg/mL) intravenous solution. The 100 mL single-dose container is by Baxter Healthcare Corporation, made in the USA. The label includes ingredient details, storage instructions, and cautions about use and container integrity.*

FDA Label Image

Principal Display Panel (51662-1480-1 CARTON)

Nexterone (amiodarone HCl) Premixed Injection 150 mg/100 mL (1.5 mg/mL) intravenous solution carton packaging. Label includes dosing strength, instructions to protect from light until use, manufacturer Baxter Healthcare Corporation, and storage information. The label displays the NDC 43066-150-10 and highlights that this is a single-dose container.*

FDA Label Image

Principal Display Panel (51662-1480-1 SERIALIZED CARTON LABELING)

Nexterone (amiodarone HCl) Premixed Injection 150 mg/100 mL (1.5 mg/mL) for intravenous use. The label indicates an iso-osmotic solution in dextrose, sterile and nonpyrogenic. It lists active and inactive ingredients, storage conditions, lot number NC128230, expiration date SEP 21, and notes to protect from light until use. Manufactured by Baxter Healthcare Corporation, distributed by HF Acquisition Co LLC.*

FDA Label Image

Principal Display Panel (51662-1481- BAG LABELING1)

Nexterone (amiodarone HCl) premixed injection label for intravenous use showing a 360 mg/200 mL (1.8 mg/mL) concentration. The label indicates a 200 mL single-dose container by Baxter Healthcare Corporation, including storage instructions and cautions. It specifies the product is sterile, nonpyrogenic, and contains iso-osmotic dextrose solution.*

FDA Label Image

Principal Display Panel (51662-1481-1 CARTON LABELING)

Packaging label for Nexterone (amiodarone HCl) Premixed Injection, 360 mg/200 mL (1.8 mg/mL) intravenous solution. The label includes usage instructions, storage conditions, and manufacturer information for Baxter Healthcare Corporation, Deerfield, IL USA. The design features red, black, white, and blue color blocks with dosage details prominently displayed.*

FDA Label Image

Principal Display Panel (51662-1481-1 SERIALIZED CARTON LABELING)

Nexterone (amiodarone HCl) Premixed Injection 360 mg/200 mL (1.8 mg/mL) for intravenous use. Iso-osmotic solution in dextrose, sterile and nonpyrogenic. Label includes active ingredient concentration, excipients, dosage and storage instructions, and manufacturer information. Distributed by HF Acquisition Co, LLC.*

FDA Label Image

Adverse (Adverse)

Table showing adverse reactions in patients receiving intravenous amiodarone, including incidence percentages from controlled and open-label studies. Reactions are grouped by body system, including fever, cardiovascular events like bradycardia, congestive heart failure, heart arrest, hypotension, ventricular tachycardia, and digestive system effects such as abnormal liver function tests and nausea, with total patient counts and percentages for each event.*

FDA Label Image

Clinical (Clinical)

A table comparing effects of intravenous and oral formulations on various cardiac parameters including SCL, QRS, QTc, AH, HV, and ERP at RA, RV, and AVN sites. The table uses arrows to indicate changes or no change for each parameter and formulation.*

FDA Label Image

Dosage 2 (Dosage 2)

A data table titled 'Table 2: Y-Site Injection Incompatibility' listing various drugs, their compatible vehicles, and corresponding amiodarone concentrations for NEXTERONE (Amiodarone HCl) intravenous injection. The table includes drugs like Aminophylline, Amoxicillin Sodium-Clavulanic Acid, and others, with vehicle types such as D5W, NS, and unknown. Concentrations range from 1.5 mg/mL to 15 mg/mL, indicating specific injection incompatibility information.*

FDA Label Image

Dosage 3 (Dosage 3)

A table titled "RECOMMENDATIONS FOR ORAL DOSAGE AFTER INTRAVENOUS INFUSION" for NEXTERONE (Amiodarone HCl). It shows oral amiodarone initial daily dose based on the duration of NEXTERONE infusion: less than 1 week (800-1600 mg), 1-3 weeks (600-800 mg), and more than 3 weeks (400 mg). Footnotes indicate assumptions about infusion rate and note NEXTERONE is not intended for maintenance treatment.*

FDA Label Image

Dosage 1 (Dosage And Administration)

A data table titled 'NEXTERONE Premixed Injection Dose Recommendations: First 24 Hours' detailing loading and maintenance infusion doses and rates for NEXTERONE (Amiodarone HCl) intravenous injection. It specifies dosages for first rapid infusion, followed by slow infusion, and maintenance infusion over designated time periods with corresponding infusion rates.*

FDA Label Image

How Supplied (How Supplied)

A data table listing two Nexterone (Amiodarone HCl) injection solution product configurations by dosage and National Drug Code (NDC). It shows 150 mg/100 mL with NDC 43066-150-10 and 360 mg/200 mL with NDC 43066-360-20, alongside associated numeric codes in a third column.*

FDA Label Image

Structure (Structure)

Chemical structure of amiodarone HCl, the active ingredient in NEXTERONE (AMIODARONE HCl) injection solution. The diagram shows the molecular framework with iodine, chlorine, oxygen, nitrogen atoms, and carbon chains as part of the compound's structure.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.